O.P.R. Development

OPR Development is the dedicated research and development subsidiary of Laboratorios Salvat, a leading Spanish pharmaceutical group. Based in Barcelona, the company focuses on the innovation and clinical development of advanced drug delivery systems and specialized formulations, particularly in the fields of otology and ophthalmology. OPR Development is responsible for the creation of several globally recognized products, including the otic combination of ciprofloxacin and fluocinolone acetonide used to treat ear infections. The company operates by advancing internal candidates through clinical trials and securing strategic licensing agreements with international partners for global commercialization. Its expertise spans from early-stage drug discovery to regulatory approval, maintaining a strong pipeline of treatments for ocular and otic conditions.